LA
SUPN icon

Lee Ainslie’s Supernus Pharmaceuticals SUPN Stock Holding History

Lee Ainslie’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,409
Closed -$223K – 483
2023
Q2 		$223K Sell
7,409
-997
-12% -$34.9K ﹤0.01% 385
2023
Q1 		$305K Buy
8,406
+695
+9% +$26.7K 0.01% 413
2022
Q4 		$275K Sell
7,711
-1,175
-13% -$40.8K 0.01% 309
2022
Q3 		$301K Buy
+8,886
New +$289K 0.01% 225
2022
Q1 		– Sell
-4,000
Closed -$117K – 363
2021
Q4 		$117K Sell
4,000
-37,962
-90% -$1.15M ﹤0.01% 175
2021
Q3 		$1.12M Sell
41,962
-15,289
-27% -$410K 0.01% 273
2021
Q2 		$1.76M Buy
+57,251
New +$1.76M 0.02% 183
2021
Q1 		– Sell
-1,711
Closed -$43K – 854
2020
Q4 		$43K Sell
1,711
-64,466
-97% -$1.39M ﹤0.01% 627
2020
Q3 		$1.38M Buy
+66,177
New +$1.5M 0.03% 199

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Lee Ainslie's SUPN Position: Q3 2023 in Review

Lee Ainslie sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 7,409 shares — an estimated $223K sold.

Lee Ainslie first reported a position in SUPN in Q3 2020 and held it in 9 quarters. The position peaked at $1.76M in Q2 2021. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • Lee Ainslie reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Lee Ainslie sold 7,409 Supernus Pharmaceuticals shares in Q3 2023, an estimated $223K.
  • Lee Ainslie first reported a position in Supernus Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Lee Ainslie's Supernus Pharmaceuticals position peaked at $1.76M in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.